COMMUNIQUÉS West-GlobeNewswire

Atsena Therapeutics Reports New Preclinical Data Demonstrating Robust MYO7A Expression and Favorable Safety for ATSN-301, a Laterally Spreading Dual AAV Vector-based Gene Therapy for Usher Syndrome Type 1B
30/10/2026
Dual vector and AAV.SPR technologies combine to drive supraphysiological levels of full-length MYO7A in non-human primate retina, reaching the macula without foveal detachment Six-month GLP toxicology study establishes [...]
Alps Group Inc Announces Shareholder Approval for a Share Consolidation, Share Capital Increase, and Adoption of Second Amended and Restated Memorandum and Articles of Association
30/10/2026
KUALA LUMPUR, Malaysia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced that its shareholders [...]
BioNexus Launches New Corporate Website with Expanded Business and Investor Resources
30/10/2026
Redesigned site brings together information on BGLC’s operating businesses, healthcare initiatives and public disclosures KUALA LUMPUR, Malaysia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC [...]
Femasys Appoints John Moorhead to Board of Directors
30/10/2026
ATLANTA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the [...]
Press Release Biocartis NV: Biocartis to Present Initial Development Data for Ultra-Rapid Idylla™ Breast21 Assay at SABCS 2026
30/10/2026
PRESS RELEASE, October 30, 2026 – 08:00 CDT Biocartis to Present Initial Development Data for Ultra-Rapid Idylla™ Breast21 Assay at SABCS 2026 ITASCA, IL, US – October 30, 2026. Today, Biocartis , an innovative [...]
Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases
30/10/2026
- Revuforj is the first and only menin inhibitor that is approved for adults and children one year and older with R/R NPM1m AML and KMT2A translocated acute leukemia - NEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Syndax [...]
Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit
30/10/2026
Presentation to explore the potential of RNA-splicing payloads to drive broad anti-tumor effects through direct cell killing along with immune activation Satyajit Mitra, Executive Director, Head of Oncology, to discuss [...]
Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin
30/10/2026
Strategic Combination Brings Highly Innovative Late-Stage D-Fi Franchise Targeting Rare Diseases, with Orphan Drug-Designated Lead Indication in Dystrophic Epidermolysis Bullosa (DEB) Combines Two Complementary [...]
NeOnc’s Ambitious Brain Cancer Plans are Setting the Stage
30/10/2026
500 Patients, 30 Hospitals, 3 Countries is Part of the Setup DENVER, Oct. 30, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews.com ) — In a market where the latest whizbang trends often dominate investor attention, NeOnc [...]
Why Kraig Labs’ Spider Silk Could Have a Future in Aerospace
30/10/2026
An Equipment Innovator’s Interest in Kraig’s High Tech Fibers Indicates Potential Applications for Lightweight and/or Tough Materials, and Possibly Elevate Project Atlas DENVER, Oct. 30, 2026 (GLOBE NEWSWIRE) -- ( www. [...]
Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
30/10/2026
First FDA-approved biologic specifically designed to cross blood-brain barrier wins award dedicated to exceptional scientific leadership and transformational impact on patient care First new FDA-approved treatment [...]
Boehringer Ingelheim registers Phase III trial investigating verducatib in COPD
30/10/2026
The Phase III AIRWARD™ trial was published today on ClinicalTrials.gov (NCT07907991). 1 AIRWARD will evaluate the efficacy and safety of verducatib, an investigational oral therapy for COPD. 1 The Phase III trial will [...]
Halloween Peptide Sale 2026: Kylo Peptides Announces $1 Research Vial Sale With Orders of $200 or More
30/10/2026
SHERIDAN, Wyo., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides [ https://kylopeptides.com/ ], a U.S. research peptides supplier, today announced a limited-time Halloween sale. Customers who place an order of $200 or [...]
Asia-Pacific is rapidly gaining importance as a major pillar in global life science innovation
30/10/2026
Speaking at the Asia-Pacific Conference of German Business in Seoul, Boehringer Ingelheim Chairman of the Board of Managing Directors, Shashank Deshpande, highlights the region’s growing role Boehringer builds on its [...]
Kestra Medical Technologies to Participate in Upcoming Investor Conferences
30/10/2026
KIRKLAND, Wash., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, is scheduled to participate in the following [...]
BrightSpring Health Services, Inc. Reports Third Quarter 2026 Financial Results and Increases Full Year 2026 Guidance
30/10/2026
LOUISVILLE, Ky., Oct. 30, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home- and community-based health services for complex [...]
Repligen Announces $1 Billion Private Convertible Senior Notes Transaction
30/10/2026
WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) (“Repligen”), today announced that it entered into privately negotiated exchange and/or subscription agreements with certain holders [...]
Regeneron Reports Third Quarter 2026 Financial and Operating Results
30/10/2026
Third quarter 2026 revenues increased 36% to $5.1 billion versus third quarter 2025 Dupixent ® global net sales (recorded by Sanofi) increased 35% to $6.5 billion EYLEA HD ® U.S. net sales increased 62% to $699 million [...]
Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA
30/10/2026
FDA recently requested additional information to evaluate whether a REMS is necessary for mitapivat in sickle cell disease FDA classified Agios’ response to the information request as a major amendment to the mitapivat [...]

Pages